Gedatolisib After a CDK4/6 Inhibitor: The Landscape Is Changing in PIK3CA-Mutant Breast Cancer

The Post-CDK4/6 Era: The New Bottleneck in Breast Oncology

HR-positive, HER2-negative breast cancer is the most common breast cancer subtype. In metastatic disease, adding CDK4/6 inhibitors to endocrine treatments such as an aromatase inhibitor or fulvestrant substantially changed first-line treatment. Many patients can now achieve prolonged disease control without chemotherapy in the first line.

However, this success brought a new problem: progression after a CDK4/6 inhibitor. At this point, understanding which biological escape route the tumor is using becomes crucial. An ESR1 mutation may dominate in one patient, the PI3K-AKT-mTOR pathway may be activated in another, and endocrine dependence may have weakened in a third. Therefore, second-line treatment is now becoming a strategy selected according to the molecular map, rather than simply “the next hormonal treatment.”

This is where the significance of VIKTORIA-1 begins. In PIK3CA-mutant patients, the study directly challenges the previously used standard approach targeting PIK3 alpha and tests whether broader PI3K/mTOR blockade could be more effective.

Why Is the PIK3CA Mutation So Crucial?

PIK3CA is one of the most frequently altered driver genes in HR+/HER2- breast cancer. This mutation may give cancer cells an advantage in growth, survival and escape from the pressure of endocrine therapy. Therefore, targeting the PI3K-AKT-mTOR axis in PIK3CA-mutant disease is a biologically strong strategy.

One of the first major breakthroughs in this field was alpelisib + fulvestrant. In the SOLAR-1 study of PIK3CA-mutant HR+/HER2- advanced breast cancer, median progression-free survival increased to 11,0 months , while in the placebo + fulvestrant arm it was 5,7 months . However, in real-world practice and in the post-CDK4/6 setting, the tolerability of alpelisib has not always been straightforward, particularly because of hyperglycemia, rash and gastrointestinal side effects.

The Same Study, Two Biological Cohorts: PIK3CA-WT and PIK3CA-Mutant

VIKTORIA-1 is a phase 3, open-label, randomized study evaluating gedatolisib-based combinations in patients with HR+/HER2- advanced breast cancer who developed progression after a CDK4/6 inhibitor + an aromatase inhibitor. A key feature is its separate evaluation of patients according to PIK3CA status.

Why Did the Early Signal From the PIK3CA-WT Cohort Matter?

In the VIKTORIA-1 PIK3CA-WT cohort, gedatolisib-based combinations had shown a substantial PFS advantage. This mattered beyond expectations because conventional PI3K alpha-targeted therapies were already not considered biologically appropriate options for patients without a PIK3CA mutation. Nevertheless, pan-PI3K/mTOR inhibition delivered a strong signal in the setting of endocrine resistance.

These data from the PIK3CA-WT cohort strengthened the idea that gedatolisib might be effective not only in PIK3CA-mutant tumors but also across a broader biology of endocrine resistance. However, the PIK3CA-mutant cohort was a more challenging clinical test because its control arm was not fulvestrant alone, but alpelisib + fulvestrant, one of the active standards.

Gedatolisib Is Being Tested Against Alpelisib, Rather Than After It

The VIKTORIA-1 PIK3CA-mutant cohort is therefore crucial: the study compares gedatolisib not simply with a weak control such as “placebo” or “fulvestrant alone,” but with the established PIK3CA-mutant targeted option in this field, alpelisib + fulvestrant .

This makes a major difference to clinical interpretation. A positive result means more than simply “gedatolisib works”; it conveys a more ambitious message: in PIK3CA-mutant HR+/HER2- advanced breast cancer after CDK4/6 treatment, more comprehensive inhibition of the PAM pathway may be more powerful than targeting PI3K alpha alone.

Different Branches of the Same Story as persevERA and SERENA-6

The ASCO 2026 breast cancer agenda is not limited to VIKTORIA-1. In the oral SERD field, studies such as persevERA and SERENA-6 highlight the idea of managing resistance to endocrine therapy earlier or more intelligently. In particular, when an ESR1 mutation develops, changing treatment at the molecular level without waiting for clinical progression may become a new paradigm in HR+/HER2- breast cancer.

However, VIKTORIA-1 occupies a different position. This study focuses not on the ESR1 axis, but on PIK3CA/PAM pathway activation . In other words, it targets a different biology of resistance in the same patient population. Therefore, after ASCO 2026, the question in clinical practice will probably be “which resistance mechanism dominates in which patient?” rather than “which drug is better?”

Alpelisib, Capivasertib and Gedatolisib: Different Nodes of the Same Pathway

The PI3K-AKT-mTOR axis does not operate like a single simple switch; it is a network of many interconnected signaling nodes. Alpelisib targets the PI3K alpha subunit. Capivasertib acts at the AKT level. Gedatolisib aims for broader PAM blockade through all PI3K isoforms and mTORC1/2.

Why Is Palbociclib Being Reintroduced?

One interesting aspect of VIKTORIA-1 is the reuse of palbociclib in the triplet arm despite patients having previously received a CDK4/6 inhibitor. This approach can be seen as a more biological version of the debate about “continuing CDK4/6 after CDK4/6.”

The assumption is that the tumor may not have become completely independent of CDK4/6 inhibition; if the main escape route comes through the PI3K-AKT-mTOR axis, suppressing it with gedatolisib may make some CDK4/6 sensitivity meaningful again. One of the most important questions at ASCO 2026 will be how much additional benefit triplet treatment provides over doublet treatment and whether that added benefit is worth the toxicity.

Tolerability Will Be as Decisive as Efficacy

For drugs targeting the PI3K-AKT-mTOR axis, the safety profile may determine the course of clinical use. Hyperglycemia and rash are important for alpelisib, stomatitis and metabolic effects for mTOR inhibitors, and diarrhea and rash for AKT inhibitors. Gedatolisib's broader PAM blockade may theoretically provide a substantial efficacy advantage, but it also requires careful monitoring of the safety profile.

Celcuity's topline announcement reports that both gedatolisib regimens were generally well tolerated in the PIK3CA-mutant cohort, that their safety profile was manageable and that no new safety signals were observed. However, this statement does not substitute for detailed toxicity rates. The actual clinical picture will become clearer when the rates of grade 3 or higher stomatitis, hyperglycemia, rash, diarrhea, treatment discontinuation and the need for dose reductions are disclosed.

The Question After ASCO: ESR1, PIK3CA or PAM?

Second-line treatment in HR+/HER2- advanced breast cancer no longer follows a single path. When disease progresses after a CDK4/6 inhibitor, biomarkers are the key factors guiding treatment. Oral SERD strategies may be considered if an ESR1 mutation is present; combinations targeting the pathway if there is a PIK3CA mutation or PI3K-AKT-mTOR activation; and chemotherapy or antibody-drug conjugates in rapid, symptomatic visceral progression.

Gedatolisib Could Redraw the Second-Line Treatment Map in HR+/HER2- Breast Cancer

The VIKTORIA-1 PIK3CA-mutant cohort is a candidate to become one of the most important breast cancer topics at ASCO 2026. This is not merely because a positive phase 3 result has been announced, but because the study directly seeks an answer to a strong clinical question: in PIK3CA-mutant HR+/HER2- advanced breast cancer after a CDK4/6 inhibitor, could more comprehensive PI3K/mTOR blockade be better than the current PIK3CA-targeted standard?

According to Celcuity's topline announcement of 1 May 2026, both gedatolisib + palbociclib + fulvestrant and gedatolisib + fulvestrant, compared with alpelisib + fulvestrant, achieved statistically and clinically meaningful superiority in progression-free survival. This information is exciting on its own, but its actual clinical weight will be determined by the median PFS, HR, response rate, treatment discontinuation rate and toxicity tables to be disclosed at ASCO.

If the results are strong and the safety profile is manageable, gedatolisib could become not only a new option in PIK3CA-mutant disease but also one of the new biomarker-based treatment backbones in the post-CDK4/6 setting of HR+/HER2- advanced breast cancer. Therefore, alongside endocrine resistance studies such as persevERA and SERENA-6, VIKTORIA-1 should be followed as one of the most striking breast cancer datasets in molecularly targeted treatment at ASCO 2026.